Sort
30,917 grants matching “tumor microenvironment”
Lysosome Trapped FAP-Targeted Theranostics for Pancreatic Cancer
$621,119Jered C Garrison · University Of Nebraska Medical Center · R01 · FY2024 · CA
Imaging Modulation of Immune Phenotype
$621,116Katherine W Ferrara · Stanford University · R01 · FY2024 · CA
Data Generation
$621,039James Korkola · Oregon Health & Science University · U54 · FY2015 · HG
Development of TGF-beta antagonists for cancer therapy
$621,015Lalage Wakefield · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
$621,000Stuart J Kahn · Syntrix Biosystems, Inc. · R44 · FY2017 · CA
Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer
$620,943Rebecca L Aft · Washington University · R01 · FY2024 · CA
Toward translation of a plant virus-based in situ vaccination nanotechnology
$620,922Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2025 · CA
Molecular Basis and Regulatory Mechanisms of Exosome Secretion
$620,906Wei Guo · University Of Pennsylvania · R35 · FY2022 · GM
Molecular Basis and Regulatory Mechanisms of Exosome Secretion
$620,906Wei Guo · University Of Pennsylvania · R35 · FY2023 · GM
Molecular Basis and Regulatory Mechanisms of Exosome Secretion
$620,906Wei Guo · University Of Pennsylvania · R35 · FY2024 · GM
Molecular Basis and Regulatory Mechanisms of Exosome Secretion
$620,906Wei Guo · University Of Pennsylvania · R35 · FY2025 · GM
(8) Genomic determinants of the T-cell regulome in immune checkpoint blockade
$620,860Tomas Kirchhoff · New York University School Of Medicine · R01 · FY2018 · CA
HLA B44 motif neoepitopes in NSCLC: Evaluating their effects on the TME and adding them to established markers in a model to predict durable benefit from PD- 1 inhibition with and without chemotherapy
$620,831Edward B Garon · University Of California Los Angeles · R01 · FY2023 · CA
Investigating CREB5-driven mechanisms of immune therapy resistance
$620,820Robert Thomas Manguso · Massachusetts General Hospital · R01 · FY2025 · CA
CANCAN-RUTGERS
$620,805Eileen White · Rutgers Biomedical And Health Sciences · OT2 · FY2024 · CA
INTEGRATING TUMOR GENETICS AND MICROENVIRONMENT AS PREDICTORS OF RESPONSE AND RESISTANCE TO IMMUNOTHERAPY IN OVARIAN CANCER
$620,791Trustees Of The University Of Pennsylvania, The · · FY2021 · Defense Health Agency
Defining the landscape of bacterial-colonized microniches in tumors and their role in intratumoral heterogeneity.
$620,787Susan Bullman · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Targeting cellular senescence to inhibit the development and progression of ovarian endometriomas
$620,760Shannon Michelle Hawkins · Indiana University Indianapolis · R01 · FY2024 · HD
Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma
$620,672Sandra P D'angelo · Sloan-Kettering Inst Can Research · R01 · FY2024 · FD
Cellular Senescence and Control of Gene Expression
$620,645Judith Campisi · Buck Institute For Research On Aging · R37 · FY2010 · AG
DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS
$620,575Nicholas Navin · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS
$620,575Nicholas Navin · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression
$620,565Heide L Ford · University Of Colorado Denver · R01 · FY2018 · CA
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression
$620,565Heide L Ford · University Of Colorado Denver · R01 · FY2021 · CA
Role of Eya3 in regulating the immune microenvironment to promote breast tumor progression
$620,565Heide L Ford · University Of Colorado Denver · R01 · FY2020 · CA